{'52WeekChange': 0.12155807,
 'SandP52WeekChange': 0.0644362,
 'address1': '26 Landsdowne Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 22.94,
 'askSize': 1000,
 'averageDailyVolume10Day': 58187,
 'averageVolume': 88223,
 'averageVolume10days': 58187,
 'beta': None,
 'beta3Year': None,
 'bid': 16.11,
 'bidSize': 1000,
 'bookValue': 4.527,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 18.065,
 'dayLow': 16.59,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.704,
 'enterpriseToRevenue': 399.542,
 'enterpriseValue': 299656608,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 18.752571,
 'fiftyTwoWeekHigh': 22.96,
 'fiftyTwoWeekLow': 4.37,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 11618889,
 'forwardEps': -3.36,
 'forwardPE': -4.9702387,
 'fromCurrency': None,
 'fullTimeEmployees': 73,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.16325001,
 'heldPercentInstitutions': 0.67190003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/fulcrumtx.com',
 'longBusinessSummary': 'Fulcrum Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on developing '
                        'products for improving the lives of patients with '
                        'genetically defined diseases in the areas of high '
                        'unmet medical need in the United States. Its product '
                        'candidates are losmapimod, a small molecule that is '
                        'in Phase 2b clinical trial for the treatment of '
                        'facioscapulohumeral muscular dystrophy, a rare, '
                        'progressive, and disabling muscle wasting disorder '
                        'that leads to significant physical impairments and '
                        'disability; and FTX-6058, a small molecule designed '
                        'to upregulate fetal hemoglobin in patients with '
                        'sickle cell disease and Ã\x9f-thalassemia. The '
                        'company is also discovering drug targets for the '
                        'treatments of duchenne muscular dystrophy, friedreich '
                        'ataxia, myotonic dystrophy 1, and '
                        'a-synucleinopathies, as well as neurological and '
                        'pulmonary diseases. Fulcrum Therapeutics, Inc. has '
                        'research and discovery collaboration agreement with '
                        'Acceleron Pharma Inc. to identify biological targets '
                        'to modulate specific pathways associated with a '
                        'targeted indication within the pulmonary disease '
                        'space; and has a strategic collaboration and license '
                        'agreement with MyoKardia, Inc. to discover, develop, '
                        'and commercialize novel targeted therapies for the '
                        'treatment of genetic cardiomyopathies. Fulcrum '
                        'Therapeutics, Inc. was founded in 2015 and is '
                        'headquartered in Cambridge, Massachusetts.',
 'longName': 'Fulcrum Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 457623456,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_376267397',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -68373000,
 'nextFiscalYearEnd': 1640908800,
 'open': 17.62,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.9,
 'phone': '617 651 8851',
 'previousClose': 17.62,
 'priceHint': 2,
 'priceToBook': 3.6889775,
 'priceToSalesTrailing12Months': 610.1646,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 18.065,
 'regularMarketDayLow': 16.59,
 'regularMarketOpen': 17.62,
 'regularMarketPreviousClose': 17.62,
 'regularMarketPrice': 17.62,
 'regularMarketVolume': 62773,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 27402600,
 'sharesPercentSharesOut': 0.0274,
 'sharesShort': 751044,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 542560,
 'shortName': 'Fulcrum Therapeutics, Inc.',
 'shortPercentOfFloat': 0.041199997,
 'shortRatio': 6.18,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'FULC',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -14.919,
 'twoHundredDayAverage': 16.139784,
 'volume': 62773,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.fulcrumtx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}